

UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

REPORT TO: Trust Board
DATE: 29th May 2014
REPORT FROM: Peter Hollinshead, Interim Director of Financial Strategy
SUBJECT: 2014/15 Financial Position to Month 1

1. Introduction and Context

1.1. This paper provides the Trust Board with an update on performance against the key financial duties;

- Delivery against the planned deficit
- Achieving the External Financing Limit (EFL)
- Achieving the Capital Resource Limit (CRL)

1.2. The paper also provides further commentary on the key risks.

2. Key Financial Duties

2.1. The following table summarises the year to date position and full year forecast against the financial duties of the Trust.

Financial Duty	YTD Plan £'Ms	YTD Actual £'Ms	Forecast Plan £'Ms	Forecast Actual £'Ms	RAG
Delivering the Planned Surplus	(4.3)	(4.3)	(40.7)	(40.7)	G
Achieving the EFL	(1.5)	(0.5)	(8.9)	(8.9)	G
Achieving the Capital Resource Limit	0.4	1.0	34.5	34.5	G

As well as the key financial duties, a subsidiary duty, is to ensure suppliers invoices are paid within 30 days – the Better Payment Practice Code (BPPC). The year to date performance is shown in the table below

Better Payment Practice Code	Apr-14	
	Number	Value £000s
Total bills paid in the year	13,293	50,129
Total bills paid within target	6,285	35,631
Percentage of bills paid within target	47.3	71.1

Key issues

- The Trust does not have an agreed contract and as such there is a significant risk to the reported income position as this does not account for CCG proposed local fines and penalties.
- Shortfall of £6.6m on the forecast CIP delivery against the £45m target.
- The Capital Plan is currently over-committed and is predicated on Emergency Floor external funding, the commitments may be in advance of the receipt of funding.

3. Year to Date Financial Position (Month 1)

3.1. The month 1 results may be summarised as follows and as detailed in Appendix 1:

	April 2014		
	Plan £m	Actual £m	Var (Adv) / Fav £m
Income			
Patient income	56.8	56.4	(0.4)
Teaching, R&D	6.9	6.8	(0.1)
Other operating Income	3.2	3.1	(0.0)
Total Income	66.9	66.3	(0.5)
Operating expenditure			
Pay	41.2	40.7	0.5
Non-pay	26.3	26.1	0.2
Total Operating Expenditure	67.5	66.8	0.7
EBITDA	(0.7)	(0.5)	0.2
Net interest	-	-	-
Depreciation	(2.8)	(2.9)	(0.1)
PDC dividend payable	(0.9)	(0.9)	0.0
Net deficit	(4.3)	(4.3)	0.0
EBITDA %		-0.8%	

3.2. The Trust is reporting;

- A deficit at the end of April 2014 of £4.3m, which is £27k favourable to the planned surplus.
- The Trust is still forecasting delivery of the year-end financial plan of a deficit of £40.7m, subject to the risks described in this paper.

3.3 At the time of writing, the Trust does not have an agreed contract with its main commissioners. The key issues of dispute are the impact of QIPP, the baseline level of activity and the Trust's CIP income assumptions. A revised proposal has been submitted to the CCG and further escalation may be required with NHSE and NTDA input.

3.4 The significant reasons for the year to date variances against income and operating expenditure are:

Patient Care Income


- Patient care income is under performing against the Trust's Plan (0.8%). The details by point of delivery and the price/volume impact are shown in Appendix 2 for NHS patient care income.
- The key factors to highlight from the appendix are;
 - £0.2m adverse position for Transplant Services due to the temporary closure of the service in April.
 - Significant over performance, £0.5m, in emergency activity, 141 spells (2%).
 - Adverse position against the Emergency Threshold (MRET), of £0.6m.

Trust Board paper W

- 9% overperformance in elective inpatients, £0.4m
- Adverse performance against Plan for both Excluded drugs and devices, £0.2m (though the offset is seen as a reduction in non pay), and critical care, £0.4m, 3% down on bed days.

Pay

- Pay expenditure in month is £40.7m compared to the budget of £41.2m. The significant factors to note are:
 - As well as being under budget, pay costs in April are also at a lower than the March spend. The graph below shows the pay cost trend, after excluding the impact of the Alliance contract in April.
 - Continued progress in recruiting substantive nurses



Non Pay

- Non pay costs are £26.1m against a budget of £26.3m, resulting in a £0.2m favourable position. The key reason for the non-pay underspend is £0.2m underspend on excluded drugs and devices. The Trust continues to enact non pay controls across the CMGs and Corporate Directorates

3.3. A more detailed financial analysis of CMG and Corporate performance (see Appendix 3) is provided through the Executive Performance Board financial report and reviewed at the Finance and Performance Committee.

Cost Improvement Programme

Appendix 3 shows CIP performance in April by CMG and Corporate Directorate against the original CIP plan. This currently shows an adverse position of £0.5m.

The following actions are planned over the next month towards ensuring deliver of the year end £45m CIP target:

- Focused work with Clinical Management Teams

Trust Board paper W

- Work to identify and drive additional savings through a number of trust-wide schemes
- Short-term measures to reduce run-rate expenditure
- Service reviews in loss-making specialties

4. Risks

4.1. Within the financial position and year end plan there continue to be following potential risks:

- **Capacity** beyond the levels planned resulting in premium costs and the loss of elective income

Mitigation: The Trust is planning to open an additional 45 beds for which both the revenue and capital costs are within the financial plan.

- **CCG Contract (including contractual fines and penalties)**

At the time of writing, the Trust does not have an agreed contract with its main commissioners. The key issues are the impact of QIPP, the baseline level of activity and the Trust's CIP income assumptions.

A revised proposal has been submitted to the CCG and further escalation may be required with NHSE and NTDA input.

- **Referral To Treat (RTT)**

There is a risk to the delivery of the RTT target resulting in additional premium costs.

Mitigation: RTT plan performance managed through fortnightly meeting with CCG/TDA and IST to review robustness of the plan.

- **CIP Delivery**

The Trust's Annual Financial plan is predicated on delivery of £45m CIPs, which is in excess of the national efficiency rate (4%) built into tariff. The additional amount is required to reduce the underlying deficit.

Mitigation: External consultancy support from Ernst & Young, along with revised CIP governance arrangements, a weekly CIP Board and CMG Performance meetings.

- **Liquidity**

The projected £40.7m deficit creates liquidity issues for the Trust

Mitigation: Application and successful receipt of Temporary Borrowing. £15.5m received in April


- **Unforeseen events**

The Trust has very little flexibility and a minimal contingency (£3.8m, 0.5% of turnover) for unforeseen financial pressures and as such any risks above the contingency will impact on the bottom line position

Trust Board paper W

5. Balance Sheet

- 5.1. The effect of the Trust's financial position on its balance sheet is provided in Appendix 4.
- 5.2. The retained earnings reserve has reduced by the Trust's £4.3m deficit for Month 1.
- 5.3. The level of non-NHS debt has fluctuated across the year as shown in the following table:



- 5.4. The overall level of non-NHS debt at Month 1 was reduced from the year end the April 2013 position although the proportion of debt over 365 days has increased from £908k (12%) at the end of March 2014 to £1,028k (15%) in Month 1.
- 5.5. The Trust will be undertaking regular debt write-off exercises during the year by the year end which will reduce the level of outstanding aged debt. All debts to be written will already have been provided for 100% in the Trust's bad debt provision and there will be no impact on the financial position as a result of these write-offs.
- 5.6. The Better Payments Practice Code (BPPC) performance for April is disappointing but this is primarily due to the fact that a large number of payments made in April related to the £12m of overdue and unpaid invoices that were outstanding from the prior financial year. We are anticipating that the BPPC performance will improve from month 2 onwards.

6. Cash Flow Forecast

- 6.1. The Trust's cashflow forecast is provided in Appendix 5 and is consistent with the forecast income and expenditure position. Cash has increased by £13.3m from the year end and this is primarily due to the receipt of a £15.5m Temporary Borrowing Loan (TBL) from the Department of Health, which is currently repayable at the end of June.
- 6.2. We are required to submit a detailed cashflow forecast each time we apply for TBL funding and we cannot apply for this funding in advance of need and must prove that we would be overdrawn if we were not to receive the cash.
- 6.3. We have held discussions with the NTDA over the funding of our £40.7m deficit plan for the year and the £12m cash needed for the payment of the backlog invoices carried forward from

Trust Board paper W

the prior year. Both of these issues contribute to a total revenue cash requirement of £52m for the year.

- 6.4. The NTDA are currently discussing our overall cash requirement with the Department of Health, based on the two year plan that we have submitted, and they hope to reach agreement on this soon.
- 6.5. We have agreed with the NTDA that we will continue to apply for temporary TBL cash when necessary during the year until we are in a position to apply for permanent PDC funding once we have more certainty over our capital PDC requirements. We have been advised that it would be beneficial for us to submit a combined PDC application for capital and revenue funding due to the level of work involved and the timescales involved.
- 6.6. The Trust's 2014-15 plan is to achieve a year end cash balance of £277k (2013/14 Actual - £515k) based on the Income & Expenditure (I&E) deficit of £40.7m.
- 6.7. This level of planned cash equates to a negative External Financing Limit (EFL) of (£8.9m), which is a statutory financial duty that the Trust must achieve. Failure to achieve the planned level of cash means that we will not achieve our EFL.
- 6.8. The Trust's cash flow forecast to the end of 2014-15 is provided in the appendices and demonstrates when the Trust will be applying for temporary borrowing in the first half of 2014/15 until permanent financing is secured.
- 6.9. Additionally we are working with the LLR CCGs to agree for them to pay us a proportion of the total monthly SLA monies on the 1st of each month instead of the 15th. This will enable us to better manager in month fluctuations in our cashflow.

7. Capital

- 7.1. Capital expenditure at the end of April was £1.0m
- 7.2. The Capital Plan has been reviewed and the proposed changes are detailed in Appendix 6.
- 7.3. The changes support the capital for bed capacity proposals and to allow for early works to commence on the ED Floor.
- 7.4. There is a risk that the Emergency Floor external funding will be delayed which would entail commitments being made in advance of funding.
- 7.5. The summary position is as follows:

Funding	£m
Opening CRL	33.0
Safer Hospitals Technology Fund	1.2
Improving Maternity Care Settings	0.1
Donations	0.3
CRL	34.5
Assumed External Funding	7.8
Applications	42.3
As per Appendix 6	47.0
Over-Commitment	4.7

8. Conclusion

- 8.1. The Trust, at the end of month 1, has a small favourable surplus of £27k against the Planned deficit of 4.3m

9. Next Steps & Recommendations

Trust Board paper W

9.1. The Trust Board is **RECOMMENDED** to:

- **Note** the contents of this report
- **Discuss and agree** the actions required to address the key issues:
 - Lack of an agreed contract
 - Shortfall on the CIP programme
 - Managing the capital programme/aspirations and to confirm the changes to the capital programme

Appendix 1

Income and Expenditure Account for the Period Ended 30 April 2014

	April 2014		
	Plan	Actual	Variance (Adv) / Fav
	£ 000	£ 000	£ 000
Elective	5,598	5,968	370
Day Case	4,542	4,546	4
Emergency (incl MRET)	14,386	14,304	(82)
Outpatient	8,117	8,125	8
Non NHS Patient Care	458	461	3
Other	23,700	22,970	(730)
Patient Care Income	56,802	56,374	(428)
Teaching, R&D income	6,908	6,831	(77)
Other operating Income	3,166	3,127	(39)
Total Income	66,876	66,332	(544)
Pay Expenditure	41,197	40,697	500
Non Pay Expenditure	26,346	26,137	209
Total Operating Expenditure	67,543	66,834	709
EBITDA	(667)	(502)	165
Interest Receivable	8	8	0
Interest Payable	0	(3)	(3)
Depreciation & Amortisation	(2,793)	(2,928)	(135)
Surplus / (Deficit) Before Dividend and Disposal of Fixed Assets	(3,452)	(3,425)	27
Dividend Payable on PDC	(869)	(869)	0
Net Surplus / (Deficit)	(4,321)	(4,294)	27
EBITDA MARGIN		-0.76%	

Patient Care Activity and Income – YTD Performance and Price / Volume Analysis

Case mix	Plan to Date (Activity)	Total YTD (Activity)	Variance YTD (Activity)	Variance YTD (Activity %)	Plan to Date (£000)	Total YTD (£000)	Variance YTD (£000)	Variance YTD (Activity %)
Day Case	6,844	6,782	(62)	(0.91)	4,542	4,546	4	0.08
Elective Inpatient	1,763	1,921	159	9.00	5,598	5,968	370	6.60
Emergency / Non-elective Inpatient	8,364	8,505	141	1.69	14,907	15,394	487	3.27
Marginal Rate Emergency Threshold (MRET)	0	0	0	0.00	(521)	(1,090)	(569)	109.31
Outpatient	60,744	60,278	(466)	(0.77)	8,117	8,125	8	0.09
Emergency Department	11,700	12,418	718	6.13	1,269	1,346	77	6.06
Winter Monies	0	0	0	0.00	0	0	0	0.00
Other	701,616	701,916	300	0.04	22,431	21,624	(807)	(3.60)
Grand Total	791,030	791,819	789	0.10	56,344	55,913	(431)	(0.76)

Average tariff	Price Variance YTD %	Volume Variance YTD %	Price / Mix Variance (£000)	Volume Variance (£000)	Variance YTD (£000)
Day Case	1.0	(0.9)	45	(41)	4
Elective Inpatient	(2.2)	9.0	(134)	504	370
Emergency / Non-elective Inpatient	1.6	1.7	236	251	487
Marginal Rate Emergency Threshold (MRET)			(569)	0	(569)
Outpatient	0.9	(0.8)	70	(62)	8
Emergency Department	(0.1)	6.1	(1)	78	77
Winter Monies			0	0	0
Other			0	(807)	(807)
Grand Total	(0.9)	0.1	(354)	(77)	(431)

Financial Performance by CMG & Corporate Directorate**I&E and CIP - to April 2014**

CMG / Directorate	Net			CIP YTD		
	YTD Budget £000s	YTD Actual £000s	Variance £000s	Plan £000s	Actual £000s	Variance £000s
CMGs:						
C.H.U.G.S	3,082	3,061	-21	399	242	-158
Clinical Support & Imaging	-3,102	-3,093	9	474	439	-35
Emergency & Specialist Med	626	949	323	396	512	116
I.T.A.P.S	-3,759	-4,065	-306	209	49	-160
Musculo & Specialist Surgery	2,634	2,503	-131	301	236	-65
Renal, Respiratory & Cardiac	2,226	2,098	-129	372	345	-27
Womens & Childrens	2,960	2,998	38	518	248	-270
	4,667	4,450	-217	2,670	2,071	-599
Corporate:						
Communications & Ext Relations	-61	-60	1	6	6	0
Corporate & Legal	-284	-287	-3	7	7	0
Corporate Medical	-245	-234	11	8	8	0
Facilities	-3,348	-3,163	185	367	367	0
Finance & Procurement	-572	-569	3	27	27	0
Human Resources	-358	-347	11	17	17	0
Im&T	-819	-840	-21	5	5	0
Nursing	-1,762	-1,716	46	30	30	0
Operations	-313	-349	-36	0	0	0
Strategic Devt	-249	-198	52	17	17	0
	-8,011	-7,762	248	484	484	0
Other:						
Alliance Elective Care	0	-25	-25			
R&D	97	97	0			
Central	-1,075	-1,054	21			
	-978	-981	-3			
Total	-4,322	-4,294	27	3,154	2,555	-599

Balance Sheet

Trust Board paper W

	Mar-14 £000's Actual	Apr-14 £000's Actual	Mar-15 £000's Forecast
Non Current Assets			
Property, plant and equipment	362,465	360,188	442,516
Intangible assets	8,019	7,788	5,327
Trade and other receivables	3,123	3,311	2,253
TOTAL NON CURRENT ASSETS	373,607	371,287	450,096
Current Assets			
Inventories	13,937	13,711	14,200
Trade and other receivables	53,483	44,492	41,908
Other Assets	0	0	0
Cash and cash equivalents	515	13,850	500
TOTAL CURRENT ASSETS	67,935	72,053	56,608
Current Liabilities			
Trade and other payables	(112,726)	(102,381)	(115,364)
Dividend payable	0	(1,025)	0
Borrowings	(6,590)	(6,590)	(2,800)
Loan	0	(15,500)	
Provisions for liabilities and charges	(1,585)	(1,585)	(426)
TOTAL CURRENT LIABILITIES	(120,901)	(127,081)	(118,590)
NET CURRENT ASSETS (LIABILITIES)	(52,966)	(55,028)	(61,982)
TOTAL ASSETS LESS CURRENT LIABILITIES	320,641	316,259	388,114
Non Current Liabilities			
Borrowings	(5,890)	(5,794)	(8,971)
Other Liabilities	0	0	0
Provisions for liabilities and charges	(2,070)	(2,048)	(1,806)
TOTAL NON CURRENT LIABILITIES	(7,960)	(7,842)	(10,777)
TOTAL ASSETS EMPLOYED	312,681	308,417	377,337
Public dividend capital	282,625	282,625	417,819
Revaluation reserve	64,598	64,598	64,628
Retained earnings	(34,542)	(38,806)	(105,110)
TOTAL TAXPAYERS EQUITY	312,681	308,417	377,337

Trust Board paper W

Cash Flow Statement for the period ended 30 April 2014			
	2014-15	2014-15	2014-15
	Apr	Apr	Apr
	Plan	Actual	Variance
	£ 000	£ 000	£ 000
CASH FLOWS FROM OPERATING ACTIVITIES			
Operating surplus before Depreciation and Amortisation	(600)	(502)	98
Donated assets received credited to revenue and non cash		(13)	(13)
Interest paid	(38)	(68)	(30)
Movements in Working Capital:			
- Inventories (Inc)/Dec	-	226	226
- Trade and Other Receivables (Inc)/Dec	(1,215)	8,991	10,206
- Trade and Other Payables Inc/(Dec)	(9,237)	(9,320)	(83)
- Provisions Inc/(Dec)	585	22	(563)
PDC Dividends paid	-	-	-
Other non-cash movements	-	132	132
Net Cash Inflow / (Outflow) from Operating Activities	(10,505)	(532)	9,973
CASH FLOWS FROM INVESTING ACTIVITIES			
Interest Received	8	7	(1)
Payments for Property, Plant and Equipment	(3,533)	(1,037)	2,496
Capital element of finance leases	(761)	(603)	158
Net Cash Inflow / (Outflow) from Investing Activities	(4,286)	(1,633)	2,653
CASH FLOWS FROM FINANCING ACTIVITIES			
New PDC / LOAN	15,500	15,500	-
Other Capital Receipts	-	-	-
Net Cash Inflow / (Outflow) from Financing	15,500	15,500	-
Opening cash	515	515	-
Increase / (Decrease) in Cash	709	13,335	12,626
Closing cash	1,224	13,850	12,626

Cashflow 12 month forecast April 2014 to March 2015	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar
	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s	£000s
Cash Flows from Operating Activities												
Operating Surplus/(Deficit)	(3,393)	(2,652)	(2,465)	553	(2,138)	281	(43)	(4,256)	(3,718)	(2,578)	(6,369)	(1,991)
Depreciation and Amortisation	2,793	2,793	2,794	2,784	2,784	2,784	2,729	2,729	2,729	2,691	2,691	2,695
Impairments and Reversals	0	0	0	0	0	(1,445)	0	0	0	0	0	0
Interest Paid	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)	(38)
Dividend (Paid)/Refunded	0	0	0	0	0	(6,118)	0	0	0	0	0	(6,118)
(Increase)/Decrease in Trade and Other Receivables	(2,415)	(1,070)	83	(3,322)	2,898	(979)	(2,054)	3,929	(1,095)	(1,062)	4,070	(4,810)
(Increase)/Decrease in Other Current Assets	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200	1,200
Increase/(Decrease) in Trade and Other Payables	(9,237)	(4,762)	(1,131)	889	1,070	(7,885)	2,306	(535)	(212)	2,041	1,864	(3,845)
Provisions Utilised	(22)	(22)	(22)	(22)	(22)	(1,022)	(22)	(22)	(22)	(22)	(22)	(25)
Increase/(Decrease) in Movement in non Cash Provisions	607	958	907	1,060	888	880	1,156	814	871	713	889	889
Net Cash Inflow/(Outflow) from Operating Activities	(10,505)	(3,593)	1,328	3,104	6,642	(12,342)	5,234	3,821	(285)	2,945	4,285	(12,043)
CASH FLOWS FROM INVESTING ACTIVITIES												
Interest Received	8	8	8	8	8	8	8	8	8	8	8	8
(Payments) for Property, Plant and Equipment	(3,533)	(3,634)	(3,630)	(4,532)	(4,761)	(4,198)	(5,003)	(3,693)	(4,564)	(5,757)	(6,751)	(7,734)
Net Cash Inflow/(Outflow) from Investing Activities	(3,525)	(3,626)	(3,622)	(4,524)	(4,753)	(4,190)	(4,995)	(3,685)	(4,556)	(5,749)	(6,743)	(7,726)
NET CASH INFLOW/(OUTFLOW) BEFORE FINANCING	(14,030)	(7,219)	(2,294)	(1,420)	1,889	(16,532)	239	136	(4,841)	(2,804)	(2,458)	(19,769)
CASH FLOWS FROM FINANCING ACTIVITIES												
New Public Dividend Capital received in year: PDC Capital						8,000						9,534
New Public Dividend Capital received in year: PDC Revenue	15,500	8,000	3,000	2,000		9,000			6,000	3,000	4,000	2,943
Loans received from DH - Revenue Support Loans	0	0	0	0	0	0	0	0	0	0	0	0
Loans repaid to DH - Revenue Support Loans Repayment of Principal							0	0	0	0	0	0
Capital element of payments relating to PFI, LIFT Schemes and finance leases	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)	(761)
Net Cash Inflow/(Outflow) from Financing Activities	14,739	7,239	2,239	1,239	(761)	16,239	(761)	(761)	5,239	2,239	3,239	18,739
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	709	20	(55)	(181)	1,128	(293)	(522)	(625)	398	(565)	781	(1,030)
Cash and Cash Equivalents (and Bank Overdraft) at Beginning of the Period	512	1,221	1,241	1,186	1,005	2,133	1,840	1,318	693	1,091	526	1,307
Cash and Cash Equivalents (and Bank Overdraft) at the end of the period	1,221	1,241	1,186	1,005	2,133	1,840	1,318	693	1,091	526	1,307	277

Trust Board paper W

Capital Plan 2014/15

Version 11 - May2014

	Scheme Committed (Y/N)	Version 08 £ ' 000	Changes £ ' 000	Version 11 £ ' 000	Project Lead	Project Director
CHUGGS CMG						
Endoscopy GH	N	309		309	Capital Planning & Delivery Team	Kate Shields
Lithotripter Machine	N	430	0	430	Michael Natrass	John Jameson
Sub-total: CHUGGS CMG		739	0	739		
CSI CMG						
Aseptic Suite	Y	400		400	Pharmacy	Suzanne Khalid
MES Installation Costs	N	1,250	-248	1,002	Helen Seth / Nigel Bond	Suzanne Khalid
Sub-total: CSI CMG		1,650	-248	1,402		
Women's and Children's CMG						
Maternity Interim Development	Y	1,000	0	1,000	David Yeomanson	Ian Scudamore
Bereavement Facilities	N	62		62	David Yeomanson	Ian Scudamore
Sub-total: Women's & Children's CMG		1,062	0	1,062		
Renal, Respiratory & Cardiac CMG						
Renal Home Dialysis Expansion	N	708		708	Samantha Leak	Nick Moore
Sub-total: Renal, Respiratory & Cardiac CMG		708	0	708		
Emergency & Specialist Medicine CMG						
DVT Clinic Air Conditioning	N	0	30	30	Jane Edyvean	Catherine Free
Sub-total: Renal, Respiratory & Cardiac CMG		0	30	30		
Corporate / Other Schemes						
Stock Management Project	N	2,949	-737	2,212	Andrea Smith	Peter Hollinshead
Medical Equipment Executive Budget	N	3,737	-500	3,237	Paul Spiers / Mark Norton	Kevin Harris
LiA Schemes	N	500	-250	250	Michelle Cloney	John Adler
Odames Library	N	1,500	-500	1,000	Capital Planning & Delivery	Kate Shields
Donations	N	300		300		Peter Hollinshead
Sub-total: Corporate / Other Schemes		8,986	-1,987	6,999		
IM&T Schemes						
IM&T Sub Group Budget	N	3,000	-1,000	2,000	IT - John Clarke	John Adler
Safer Hospitals Technology Fund	N	1,150		1,150	IT - John Clarke	John Adler
EDRM System	N	3,300		3,300	IT - John Clarke	John Adler
EPR Programme	N	3,100		3,100	IT - John Clarke	John Adler
Unified Comms	N	1,850		1,850	IT - John Clarke	John Adler
Sub-total: IM&T Schemes		12,400	-1,000	11,400		
Facilities / NHS Horizons Schemes						
Facilities Backlog Maintenance	N	6,000	-500	5,500	Horizons - Andrew Chatten	Rachel Overfield
Accommodation Refurbishment	N	2,400	-1,200	1,200	Clare Blakemore / Andrew Chatten	Kate Bradley
CHP Units LRI & GH	Y	800		800	Horizons - Nigel Bond	Rachel Overfield
Sub-total: Facilities / NHS Horizons Schemes		9,200	-1,700	7,500		
ED Enabling Schemes						
ED Enabler: Clinic 1 & 2 Works	N	814		814	Capital Planning & Delivery/Louise Na	Kate Shields
ED Enabler: Old Cancer Centre Conversion	N	1,050		1,050	Capital Planning & Delivery/Louise Na	Kate Shields
ED Enabler: Oliver Ward Conversion	N	1,260		1,260	Capital Planning & Delivery/Louise Na	Kate Shields
ED Enabler: Clinical Genetics	N	158		158	Capital Planning & Delivery/Louise Na	Kate Shields
ED Enabler: Chapel Relocation	N	315		315	Capital Planning & Delivery/Louise Na	Kate Shields
ED Enabler: Victoria Main Reception	N	525		525	Capital Planning & Delivery/Louise Na	Kate Shields
ED Enabler: Modular Wards LRI	Y	3,700		3,700	Capital Planning & Delivery/Louise Na	Kate Shields
Sub-total: ED Enabling schemes		7,822	0	7,822		
ED Early Works	N		3,500	3,500	Capital Planning & Delivery	Kate Shields
Reconfiguration Schemes						
Theatre Recovery LRI	N	2,785	-270	2,515	Capital Planning & Delivery/Ian Currie	Kate Shields
Interim ITU LRI	Y	500		500	Capital Planning & Delivery	Kate Shields
Vascular Enabling	N	520	-520	0	Capital Planning & Delivery/Debra Gre	Kate Shields
KSOPD Refurbishment	N	250	-250	0	Capital Planning & Delivery	Kate Shields
Ward 4 LGH	N	1,000		1,000	Capital Planning & Delivery/Nicky Topl	Kate Shields
Additional Beds (GH & LRI)	N	0	1,750	1,750	Capital Planning & Delivery	Kate Shields
Feasibility Studies	N	100		100	Capital Planning & Delivery	Kate Shields
Sub-total: Reconfiguration Schemes		5,155	710	5,865		
Total Schemes funded via internal sources		47,722	-695	47,027		
CRL Funding		34,507	0	34,507		
ED Enabling Schemes (assumed external funding)		7,822	0	7,822		
CRL Funding Gap		5,393	-695	4,698		
Schemes to be funded via external loans						
Emergency Floor	N	11,523	-5,523	6,000	Capital Planning & Delivery/Nicky Topl	Kate Shields
GGH Vascular Surgery 9inc.Ward, Ang, Hybrid	N	4,000	-1,500	2,500	Capital Planning & Delivery/Rachel Gri	Kate Shields
Sub-total: External Loans		15,523	-7,023	8,500		
Total Capital Plan		63,245	-7,718	55,527		

Appendix 6